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Deterioration of functional islet b-cell mass is the
final step in progression to Type 2 diabetes. We
previously reported that overexpression of Nkx6.1
in rat islets has the dual effects of enhancing
glucose-stimulated insulin secretion (GSIS) and in-
creasing b-cell replication. Here we show that Nkx6.1
strongly upregulates the prohormone VGF in rat
islets and that VGF is both necessary and sufficient
for Nkx6.1-mediated enhancement of GSIS. More-
over, the VGF-derived peptide TLQP-21 potentiates
GSIS in rat and human islets and improves glucose
tolerance in vivo. Chronic injection of TLQP-21 in
prediabetic ZDF rats preserves islet mass and slows
diabetes onset. TLQP-21 prevents islet cell apo-
ptosis by a pathway similar to that used by GLP-1,
but independent of the GLP-1, GIP, or VIP receptors.
Unlike GLP-1, TLQP-21 does not inhibit gastric
emptying or increase heart rate. We conclude that
TLQP-21 is a targeted agent for enhancing islet
b-cell survival and function.
INTRODUCTION
Pancreatic islet b-cells perform a critical role in the regulation of
whole animal fuel homeostasis by secreting insulin in response
to nutritional and hormonal signals. Deterioration of b-cell
mass and function are key events in the development of type 2
diabetes (T2D) (Muoio and Newgard, 2008). Multiple pharmaco-
therapies exist for treating T2D, each with distinct impacts on
b-cell mass and function. Sulfonylureas directly stimulate insulin
release, but when given chronically may exacerbate b-cell failure
(Efanova et al., 1998; Maedler et al., 2005). Insulin-sensitizing
agents such as the thiazolidinediones (TZD) and metformin can
delay and/or prevent loss of islet b-cell mass in rodents and
humans, despite exerting their effects primarily in peripheral
tissues (Finegood et al., 2001; Kahn et al., 2006; Ovalle andBell, 2002). Finally, emerging incretin-based therapies such as
the stable GLP-1R agonists, exenatide and liraglutide, and the
DPP-4 inhibitors sitagliptin and saxagliptin, enhance islet b-cell
function and survival (Ahre´n et al., 2000; Drucker and Nauck,
2006; Reimer et al., 2002; Stoffers et al., 2000; Xu et al., 1999).
However, the ability of GLP-1 therapies to promote b-cell
survival in the context of human T2D is not fully understood, in
part due to the absence of methods for measuring human islet
mass in situ. Also, b-cell secretagogues have traditionally suf-
fered from a loss of efficacy over time; whether this will be a
problem for GLP-1-based therapeutics has yet to be deter-
mined. Finally, GLP-1 and related peptides have significant
side effects, including gastrointestinal effects that can be suffi-
ciently severe to result in cessation of therapy in some patients.
These unresolved issues encourage continued investigation into
alternative pathways for preservation and enhancement of func-
tional b-cell mass.
We previously demonstrated that overexpression of the
homeodomain transcription factor Nkx6.1 in rat islets increases
islet b-cell replication while simultaneously enhancing glucose-
stimulated insulin secretion (GSIS) (Schisler et al., 2008,
2005). In the current study, we demonstrate that Nkx6.1 in-
duces expression of the prohormone VGF (nonacronymic; un-
related to VEGF) and that this induction explains the enhance-
ment of GSIS by Nkx6.1. We then show that the C-terminal
VGF peptide, TLQP-21, potentiates GSIS in isolated rat islets
and reduces glycemic excursion in Wistar rats following a
glucose challenge. Chronic administration of TLQP-21 to
Zucker Diabetic Fatty (ZDF) rat delays the onset of overt
diabetes by preserving islet cell mass. Subsequent in vitro
studies demonstrate that TLQP-21 is similar to exendin-4 in
blocking islet b-cell apoptosis induced by two different agents.
We demonstrate that TLQP-21 shares many of the antidiabe-
togenic properties of GLP-1R agonists (potentiates GSIS,
improves glycemic control, reduces islet cell apoptosis) yet
lacks some of the non-b-cell effects of GLP-1R agonists (in-
hibition of gastric emptying and stimulation of heart rate).
Our studies suggest that TLQP-21 represents a specific agent
for preserving b-cell mass and function during development
of T2D.Cell Metabolism 16, 33–43, July 3, 2012 ª2012 Elsevier Inc. 33
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Figure 1. Overexpression of Nkx6.1, but Not Pdx-1 Enhances GSIS and Increases VGF Expression in Primary Rat Islets
(A–D) Rat islets were treated with recombinant adenoviruses (AdCMV) expressing Nkx6.1, Pdx-1, VGF or GFP as indicated and analyzed 72 hr postviral
treatment. (A and C) Glucose-stimulated insulin secretion was measured by static incubation in media containing 2.5 mM Glc and 16.7 mM Glc for 1 hr each. (B)
Immunoblot analysis of whole cell lysates. (D) Quantitative RT-PCR was used to measure VGF mRNA levels.
(E and F) Rat islets were treated with recombinant adenoviruses expressing Ad-siVGF or Ad-siSCR for 24 hr followed by treatment with AdCMV-Nkx6.1 or
AdCMV-GFP for an additional 24 hr as indicated. Glucose-stimulated insulin secretion was measured by static incubation in media containing 11.2 mM Glc for
1.5 hr. In (A)–(F), data represent the mean ± SEM of 3 independent experiments. *p% 0.01.
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Overexpression of Nkx6.1, but Not Pdx-1 Enhances
Glucose-Stimulated Insulin Secretion
Wehave previously demonstrated that overexpression of Nkx6.1
in adult rat islets has the rare effect of simultaneously promoting
b-cell proliferation and enhancing GSIS (Schisler et al., 2008,
2005). Because Nkx6.1 and Pdx-1 are two prominent homeobox
transcription factors that are preferentially expressed in b-cells,
we compared their ability to enhance insulin secretion in the
setting of the adult islet. Treatment of rat islets with adenoviruses
containing the Nkx6.1 or Pdx-1 cDNAs caused increases
of almost 10-fold in each protein relative to a GFP control
(Figure 1B), but only Nkx6.1 overexpression caused a 35%
increase in insulin secretion at stimulatory (16.7 mM) glucose
(Figure 1A).
Based on the data shown in Figure 1A, we postulated that
genes specifically regulated by Nkx6.1 but not Pdx-1 contribute
to enhanced GSIS. We therefore performed cDNA microarray
analysis of rat islets overexpressing Nkx6.1, Pdx-1, or b-galacto-34 Cell Metabolism 16, 33–43, July 3, 2012 ª2012 Elsevier Inc.sidase (control). The Nkx6.1 array data was published previously
(Schisler et al., 2008). Genes that were increased byR 2-fold or
reduced in expression byR 50% by Nkx6.1 overexpression and
not regulated by Pdx-1 relative to control islets were identified as
potential regulators of islet b-cell function (Table S1). The nerve
growth factor-inducible gene VGF (nonacronymic; unrelated to
VEGF) was the most highly upregulated gene on this list. Con-
firming the results of the microarray data, we observed a 25-
fold upregulation of VGFmRNA (Figure 1D) and a robust increase
in pro-VGF protein levels (Figure 1B) in rat islets overexpressing
Nkx6.1, but not Pdx-1 or GFP.
VGF Expression in Rat Islets Enhances GSIS
To determine if VGF overexpression can mimic the enhanced
GSIS observed with Nkx6.1 overexpression, we generated a re-
combinant adenovirus containing the human VGF cDNA. For this
experiment, we used adenovirus titers that gave comparable
levels of VGF overexpression as obtained in response to
Nkx6.1 overexpression (data not shown). Overexpression of
VGF in primary rat islets resulted in a 46% increase in GSIS at
Cell Metabolism
TLQP-21 Preserves Islet b-Cell Mass and Functionstimulatory glucose (16.7 mM Glc) relative to the GFP
control, without affecting basal insulin secretion (2.5 mM Glc)
(Figure 1C). Neither Nkx6.1 (Schisler et al., 2008) nor VGF
overexpression changed insulin content in rat islets, and
Nkx6.1 levels were not affected by manipulation of VGF ex-
pression (data not shown). These data demonstrate that VGF
overexpression enhances GSIS in a manner similar to Nkx6.1
overexpression.
To determine if VGF upregulation is required for the Nkx6.1-
mediated enhancement of GSIS, we used a recombinant adeno-
virus to suppress VGF expression (Ad-siVGF) in rat islets. As
shown in Figures 1E and 1F, Nkx6.1 overexpression resulted in
a strong upregulation of VGF (20-fold) and a corresponding
increase in GSIS. siRNA-mediated suppression of VGF upregu-
lation in Nkx6.1 overexpressing islets (Figure 1F) reduced GSIS
to levels observed in islets treated with AdCMV-GFP (Figure 1E).
In sum, data in Figures 1C, 1E, and 1F establish that upregulation
of VGF is required for Nkx6.1-mediated enhancement of GSIS,
and that increased expression of VGF is sufficient to drive the
improved glucose response.
The C-Terminal VGF Peptide TLQP-21 Potentiates GSIS
in Rat and Human Islets
VGF is expressed as a 67 kDa prohormone and processed by
PC1/3 and PC2 to yield a number of distinct peptides (Garcia
et al., 2005; Levi et al., 2004; Trani et al., 2002). In islet cells, these
peptides are stored in large dense core granules and secreted
via the regulated secretory pathway in response to glucose
and other secretagogues (Possenti et al., 1999). C-terminal
VGF-derived peptides, including TLQP-21 and AQEE-30 (shown
in Figure 2A), have been previously documented to play distinct
roles in the central nervous system (Bartolomucci et al., 2006;
Hunsberger et al., 2007). These peptides have also been identi-
fied in islets (Cocco et al., 2007), but their biological functions
have not been reported in islet cells.
To begin to investigate the potential impact of TLQP-21 on
islet biology, we first studied the effect of acute administration
of TLQP-21 on insulin secretion in primary rat islets, using the
GLP-1R agonist, exendin-4, as a positive control. Addition of
TLQP-21 to rat islets resulted in a concentration-dependent
increase in GSIS, with significant effects observed with as little
as 5 nM peptide, and a maximal 35% increase at 50 nM (Fig-
ure 2B). In comparison, 20 nM exendin-4 enhanced GSIS by
80%. Similar to exendin-4 and consistent with the VGF overex-
pression data (Figure 1C), TLQP-21 potentiated insulin release
only at stimulatory (16.7 mM) glucose concentrations and did
not raise basal (2.5 mM Glc) insulin secretion (Figure 2B). The
concentrations of TLQP-21 required for enhancement of GSIS
are consistent with those recently reported to enhance iso-
proterenol-mediated lipolysis in 3T3 L1 adipocytes (Possenti
et al., 2012). In contrast, a second C-terminal VGF peptide,
AQEE-30, was unable to augment GSIS at any concentration
studied (Figure S1A). To assess whether naturally occurring
C-terminal extensions of the TLQP peptide could enhance the
peptide’s potency, we tested TLQP-30 and TLQP-42 (see Fig-
ure 2A). Both of these longer peptides potentiated GSIS to
a similar extent as TLQP-21 (Figure S1B).
We also tested the effect of TLQP-21 in human islet prepara-
tions from four separate donors. Similar to rat islets, 50 nMTLQP-21 enhanced insulin secretion by 42%at 16.7mMglucose
in human islets, as compared to an 82% enhancement by exen-
din-4, with no effect on basal insulin release (Figure 2D). These
results identify TLQP-21 as a VGF-derived peptide with the
capacity to potentiate GSIS in both rat and human islets.
TLQP-21 Is Secreted from Human Islets in Response to
Glucose
Based on these effects of TLQP-21, we wondered if islets
produce significant amounts of the peptide in response to phys-
iological stimuli. We therefore used an ELISA assay specific for
human TLQP-21 to measure its secretion from human islets.
We found that stimulatory (16.7mM) glucose caused a significant
2.5-fold increase in TLQP-21 release from human islets relative
to secretion at 2.5 mM glucose (Figure 2C), suggesting that local
concentrations of TLQP-21 could change with appropriate
dynamics for enhancement of insulin secretion. This observation
is consistent with earlier reports of glucose-stimulated release of
longer, C-terminal derived VGF peptides from insulinoma cells
(Possenti et al., 1999), but is to our knowledge the first demon-
stration of regulated TLQP-21 secretion from human islets.
Human islets secreted approximately 0.6 pg TLQP-21/mg islet
protein/2 hr when exposed to high glucose. This rate of produc-
tion is calculated to raise the TLQP-21 concentration in the
media to approximately 0.1 nM over 2 hr, or 1.2 nM over 24 hr.
The latter level approaches stimulatory concentrations in our
rat islet studies. It should also be noted that this calculation
does not measure higher concentrations of TLQP-21 that may
exist at the cell surfacewhen islet cells release the peptide. Since
glucose does not stimulate secretion of somatostatin from delta
cells or glucagon from alpha cells, we take our data to suggest
that at least some of the islet-derived TLQP-21 is coming from
b-cells. Total TLQP-21 content of human islets was determined
to be 87.1 ± 6.1 pmol / mg protein, compared to insulin, at
15.6 ± 2.0 nmol / mg protein.
TLQP-21 Elevates cAMP Levels in Rat Islets
Independent of Known Incretin Receptors
The receptor system(s) for VGF-derived peptides have not been
described. To begin to investigate the mechanism by which
TLQP-21 potentiates GSIS in rat islets, we measured islet
cAMP levels. Treatment of rat islets with TLQP-21 resulted in
a doubling of cAMP levels, whereas exendin-4 caused an almost
3-fold increase (Figure 2E), consistent with the more potent
effects of exendin-4 on GSIS compared to TLQP-21 in both rat
and human islets (Figures 2B and 2D).
GLP-1/exendin-4, glucose-dependent insulinotropic polypep-
tide (GIP), and vasoactive intestinal peptide (VIP) raise cAMP
in islet cells through distinct GLP-1, GIP, and VIP receptors
(GLP-1R, GIPR, and VIPR1/2, respectively). To test if TLQP-21
engages with any of these receptors to raise cAMP levels, we
transfected HEK293 cells (which lack endogenous GLP-1, GIP,
or VIP receptors) with plasmids expressing GLP-1R, GIPR, or
VIPR2 and examined cAMP accumulation following exposure
to various peptides, including TLQP-21 (Figure 2F). Exendin-4
and GIP strongly increased cAMP levels in HEK293 cells ex-
pressing their cognate receptors, but as expected, displayed
no cross-reactivity. VIP potently elevated cAMP in cells express-
ing the VIPR2, but was also able to partially activate GLP-1R andCell Metabolism 16, 33–43, July 3, 2012 ª2012 Elsevier Inc. 35
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Figure 2. The C-Terminal VGF Peptide TLQP-21 Potentiates GSIS in Rat and Human Islets
(A) Schematic of the rat/mouse VGF proprotein highlighting the C-terminal peptides TLQP-21, TLQP-30, TLQP-42, and AQEE-30. The cleavage sites are indi-
cated by the downward facing arrows with the amino acid positions labeled.
(B) Primary rat islets were assayed for insulin secretion by static incubation in media containing 2.5 mM Glc and then 16.7 mM Glc for 1 hr each. The indicated
concentrations of the VGF-derived peptide TLQP-21 were added during both the basal and stimulatory glucose incubations. Exendin-4 (20 nM) was used as
a positive control.
(C) Human islets from 3 separate donors were assayed for TLQP-21 secretion via static incubation in media containing 2.5 mMGlc and then 16.7 mMGlc for 2 hr
each.
(D) Human islets from 4 separate donors were assayed for insulin secretion using the method described in (B) including DMSO (control), TLQP-21 (50 nM) or
exendin-4 (20 nM).
(E) Rat islets were assayed for cAMP levels following a 30 min incubation in media containing 16.7 mM Glc with DMSO (control), TLQP-21 (50 nM), or exendin-4
(20 nM).
(F) HEK293 cells transfected with plasmids encoding the rat GLP-1R, the human GIPR, or human VIPR2 were incubated under basal conditions with DMSO
(control), exendin-4 (20 nM), GIP (10 nM), VIP (10 nM) or TLQP-21 (50 nM) for 15 min and cAMP levels determined. In (A–F), data represent the mean ± SEM of
three to five independent experiments. *p% 0.01; **p% 0.002.
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ing GLP-1R, GIPR, or VIPR2, indicating that TLQP-21 signaling
is mediated by a receptor distinct from those involved in known
incretin and VIP signaling pathways.
TLQP-21 Reduces Glycemic Excursion through
Increased Insulin Secretion In Vivo
We next sought to determine the impact of TLQP-21 administra-
tion on glucose tolerance and insulin action. Normal Wistar rats
were fasted overnight and TLQP-21 (4.5 mg/kg) or saline were36 Cell Metabolism 16, 33–43, July 3, 2012 ª2012 Elsevier Inc.delivered by intraperitoneal (i.p.) injection 30 min prior to a
glucose bolus. TLQP-21 did not increase circulating insulin or
induce hypoglycemia in fasted rats (Figures 3A and 3C, compare
t = 30 min versus t = 0 min). Following the glucose bolus,
animals injected with TLQP-21 exhibited a 20% reduction in
the blood glucose peak (20 min) and a persistent decrease at
later time points (Figure 3A), resulting in a 25% decrease in total
glycemic excursion as assessed by area under the curve anal-
ysis (Figure 3B). The TLQP-21-mediated decrease in blood
glucose was accompanied by a 25% increase in plasma insulin
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Figure 3. TLQP-21 Enhances Plasma Insulin Release and Reduces Glycemic Excursion in Male Wistar Rats
(A–C) Overnight (12 hr) fasted rats were injected i.p. with either vehicle (saline) or TLQP-21 (4.5 mg/kg) at 30 min prior to an i.p. glucose (1 g/kg) bolus. (A) Blood
glucose wasmonitored at the indicated times. (B) Average area under the curve (AUC) analysis for the glucose tolerance test results. (C) Blood was sampled from
the saphenous vein at the indicated times and assayed for insulin levels.
(D) Ad libitum fed rats were injected i.p. with saline, TLQP-21 (5 mg/kg) or TLQP-21 (1 mg/kg) at 30 min prior to an insulin (1 U/kg) challenge. Blood glucose was
measured at the indicated times. Data represent the mean ± SEM (A–C), n = 12; (D), n = 5). *p% 0.05, **p% 0.01.
Cell Metabolism
TLQP-21 Preserves Islet b-Cell Mass and Functionlevels (Figure 3C) demonstrating that TLQP-21 potentiates
glucose-stimulated insulin release in vivo as well as in isolated
islets (Figures 2B and 2D). We further explored the activity of
TLQP-21 at 3 doses (5 mg/kg, 1 mg/kg and 0.5 mg/kg) followed
by a glucose challenge, and observed a dose-dependent reduc-
tion in glycemic excursion (Figure S2). Again, TLQP-21 did not
reduce blood glucose in the fasted state (Figure S2, compare
t = 20 min versus t = 0 min). To test for potential effects of
TLQP-21 on insulin action, two doses of TLQP-21 were adminis-
tered to ad libitum fed rats 30 min prior to injection of insulin
(1 U/kg). Insulin-mediated decreases in blood glucose were
indistinguishable in TLQP-21-injected versus control rats, indi-
cating that TLQP-21 does not alter insulin sensitivity (Figure 3D).
Also, treatment of rat islets with TLQP-21 for 24 or 48 hr did not
alter total GLP-1 content, suggesting that the effects of TLQP-21
are not mediated by changes in islet GLP-1 (data not shown).
Overall, our studies demonstrate that TLQP-21 enhances glu-
cose tolerance in normal rats by enhancing GSIS.
TLQP-21 Treatment Does Not Reduce Gastric Emptying
or Increase Heart Rate
Having established that TLQP-21 is similar to the GLP-1R
agonist exendin-4 in its ability to enhance insulin secretion in a
glucose-dependent manner and lower blood glucose, but via
a GLP-1R-independent mechanism, we next determined if
TLQP-21 shares two prominent side effects of GLP-1/ exen-
din-4-inhibition of gastric emptying and stimulation of heart
rate (Barraga´n et al., 1994; Yamamoto et al., 2002). To examine
gastric emptying, we performed an acetaminophen absorption
test, which is based on the observation that acetaminophen is
largely absorbed in the duodenum (Hatanaka et al., 1994).Fasted animals were injected with either TLQP-21 (4.5 mg/kg),
a scrambled peptide of identical amino acid composition to
TLQP-21 (SCR-21; 4.5 mg/kg), exendin-4 (10 mg/kg), or saline
at 20 min prior to delivery of an oral bolus of acetaminophen
(100 mg/kg) given as a sugar-rich solution (children’s painkiller).
Whereas exendin-4-treated animals exhibited a profound delay
in acetaminophen appearance in peripheral blood relative to
the control groups, TLQP-21 injection had no effect on this
variable relative to saline or SCR-21 injection, indicating that
TLQP-21 does not alter gastric emptying (Figure 4A). In this
same experiment, TLQP-21 and exendin-4 increased circulating
insulin levels to a similar extent (Figure 4B), demonstrating
normal potentiation of GSIS by TLQP-21 despite its lack of effect
on the gut. To further substantiate these findings, we used a
separate experimental model of gastric emptying in which
dry stomach contents of fasted/refed animals were compared.
Once again, TLQP-21 treated animals behaved similarly to
control (saline and SCR-21-treated) animals, all with approxi-
mately 20% of stomach contents remaining 3 hr post feeding,
whereas exendin-4 treatment resulted in a profound delay in
solid food clearance from the stomach, with 66% retained
(Figure 4C).
We next examined changes in resting heart rate in animals
subjected to the various treatments (saline, TLQP-21, SCR-21,
Ex-4). Exendin-4 treatment caused a rapid increase in heart
rate (HR) of approximately 10%–12% that was sustained for
the duration of the study (Figure 4D) consistent with previously
published reports in rodents (Barraga´n et al., 1994; Yamamoto
et al., 2002). In contrast, TLQP-21 and the control treatments
(saline and SCR-1) had no effect on heart rate at any time point.
Taken together these data indicate that TLQP-21 does not causeCell Metabolism 16, 33–43, July 3, 2012 ª2012 Elsevier Inc. 37
0 15 30 45 60
0
50
100
150
200
saline
TLQP-21
SCR-21
Ex-4
**
**
Time (min)
S
e
r
u
m
a
c
e
t
a
m
in
o
p
h
e
n
  
(
µ M
)
0 10 20 30 40 50
-10
-5
0
5
10
15
20
25
saline
TLQP-21
SCR-21
Ex-4
* *
* * *
Time (min)
 H
R
 (
%
)
baseline 30 min
0.0
0.5
1.0
1.5
2.0
saline
TLQP-21
SCR-21
Ex-4
** **
S
e
r
u
m
 
i
n
s
u
l
i
n
 
(
n
g
/
m
L
)
saline TLQP-21 SCR-21 Ex-4
0
10
20
30
40
50
60
70 ***
G
a
s
t
r
ic
 e
m
p
t
y
i
n
g
 
(
%
)
A B
C D
Figure 4. TLQP-21 Does Not Alter Gastric
Emptying or Elevate Resting Heart Rate
(A–D) Male Wistar rats were fasted overnight
(12 hr). (A and B) Rats were injected i.p. with
saline, TLQP-21 (4.5 mg/kg), SCR-21 (4.5 mg/kg;
scrambled peptide of identical amino acid
composition to TLQP-21), or exendin-4 (10 mg/kg).
At 20 min post peptide injection animals received
an oral gavage of acetaminophen (100 mg/kg).
Blood was sampled at the indicated times and
serum levels of (A) acetaminophen and (B) in-
sulin were determined via colorimetric assay and
ELISA, respectively. (C) Fasted/ refed rats were
injected (i.p.) with saline, TLQP-21 SCR-21, or
exendin-4 at 1 hr post feeding. At 3 hr post peptide
injection stomach contents were retrieved. The
percentage food content remaining in the stomach
was determined as the dry weight of stomach
contents divided by the total amount of food
consumed per animal x 100. (D) Male Wistar rats
were sedated using avertin (250 mg/kg) and
resting heart rate (HR) established using con-
tinuous ECG recordings (5 min intervals). Animals then received an i.p. injection of saline, TLQP-21, SCR-21, or exendin-4 and heart rate was monitored
continuously for up to 50 min. Data are presented as the mean ± SEM (n = 7–8). *p% 0.05; **p% 0.01; ***p% 0.001.
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effects of GLP-1/ exendin-4 in rodents.
Chronic Treatment with TLQP-21 Slows Development
of Hyperglycemia in Prediabetic ZDF Rats
To evaluate the potential of TLQP-21 as an antidiabetogenic
agent, we performed a chronic (4 wk) treatment study in male
Zucker Diabetic Fatty (ZDF; fa/fa) rats. In this study, 7 wk old
animals were injected with 5 mg/kg TLQP-21 or SCR-21 control
peptide, or an equivalent volume of saline, at a frequency of
every other day for 4 wks. Note that at this stage, ZDF animals
are insulin resistant, mildly glucose intolerant, and hyperinsuli-
nemic, but have normal fasting glucose levels. At the conclusion
of the 4 week treatment period, rats injected with TLQP-21 had
a decrease in blood glucose in the fed state of 150 mg/dl
compared to rats treated with SCR-21 peptide or saline (Fig-
ure 5A). The TLQP-21-treated animals also had a striking
improvement in their response to a glucose challenge compared
to either control group (Figure 5B). In addition, fasting blood
glucose was 150 mg/dl lower in TLQP-21 treated animals
compared to control animals (Figure 5B, t = 0 min). TLQP-21-
treated animals exhibited no decrease in body weight (Fig-
ure 5C). Plasma insulin levels obtained from fasted animals
sampled at the end of the study were markedly higher in
TLQP-21-treated animals than in either of the control groups
(Figure 5D). It is important to note that animals did not receive
peptide within 24 hr of the glucose tolerance test. These studies
document a clear effect of TLQP-21 to delay onset of T2D and
improve glucose homeostasis in a rodent model, an effect that
appears to be independent of changes in body weight.
We postulated that the improvement in glycemic control
and increased fasting insulin levels in the TLQP-21-treated
animals may be due to a preservation of islet b-cell mass. Histo-
logical examination of pancreas sections from the 3 treatment
groups revealed that TLQP-21-treated ZDF rats exhibited
a 40% increase in area of insulin positive cells (a surrogate
measure of b-cell mass) compared to the two control groups38 Cell Metabolism 16, 33–43, July 3, 2012 ª2012 Elsevier Inc.(Figure 5E). Analysis of DNA fragmentation via TUNEL staining
showed that the difference in islet b-cell mass was due, at
least in part, to a decrease in b-cell apoptosis in TLQP-21
treated animals as compared to SCR-21-treated control
animals (Figure 5F). We note that overnight exposure of isolated
rat islets to the VGF peptide TLQP-21 did not enhance islet
cell proliferation as measured by [3H]-thymidine incorporation
(Figure S1C), suggesting that replication was not a major con-
tributor to TLQP-21-induced differences in islet b-cell mass in
the ZDF model.
TLQP-21 Reduces Islet Cell Death Induced by
Cytotoxins
Wenext sought todetermine if TLQP-21hasadirect antiapoptotic
effect in rat islets, as suggested by the reduced TUNEL staining in
TLQP-21 treated ZDF rats (Figure 5F), and a previous report of
antiapoptotic activity of TLQP-21 in cerebellar granular cells
deprived of serum (Severini et al., 2009). To test this hypothesis
in islets, we evaluated whether pretreatment of isolated islets
with TLQP-21 could suppress islet cell apoptosis induced by
the ER stress agent, thapsigargin. For these experiments (Figures
6A–6C), isolated isletswerepretreatedwithDMSOorTLQP-21 for
24h followed by overnight treatment (18 hr) with thapsigargin.
Islets were then dispersed and apoptotic cells identified by
TUNEL staining. As expected, treatment of rat islets with thapsi-
gargin causedamarked increase in the numberof TUNELpositive
cells compared to the vehicle (DMSO) control (Figure 6C);
however, pretreatment of rat islets with TLQP-21 reduced the
number of thapsigargin-induced TUNEL positive cells by greater
than 50% (compare Figure 6A with Figure 6B; quantification in
Figure 6C). TLQP-21 also caused a significant suppression of
apoptosis caused by chronic (72 hr) exposure of rat islets to the
DNA damage-inducing agent etoposide, and the magnitude of
this effect was again comparable to the effect of exendin-4 (Fig-
ure6D).Theseexperimentsemployedanalternativemethodology
(Annexin V staining/ flow cytometry) for measurement of apo-
ptosis. In experiments with either apoptosis inducer, protection
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Figure 5. Chronic Treatment of ZDF Rats
with TLQP-21 Improves Glucose Homeo-
stasis and Preserves Islet b-Cell Mass
(A–F) Male Zucker Diabetic Fatty (fa/fa) rats were
injected i.p. with TLQP-21 (5 mg/kg), SCR-21
(5 mg/kg), or saline every other day for 4 wks
beginning at 7 wks of age. (A) Ad libitum fed
blood glucose. (B) Overnight (12 hr) fasted rats
were given a glucose (1 g/kg) challenge (i.p.) and
blood glucose monitored at the indicated times.
(C) Body weight was measured at the indicated
times. (D) Plasma insulin levels were assayed
from overnight (12 hr) fasted rats at the end of
the treatment period. (E) b-cell mass was calcu-
lated as the percentage of insulin staining area
relative to the total area of pancreas section from
4 independent sections per animal. (F) Quantifi-
cation of the average number of TUNEL positive,
insulin positive cells per islet. Data are pre-
sented as the mean ± SEM (n = 6–8). *p % 0.05,
**p% 0.01.
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TLQP-21 Preserves Islet b-Cell Mass and Functionafforded by treatment with 50–100 nM TLQP-21 was similar to
that observed in islets treated with 20 nM exendin-4 (Figures 6C
and 6D). Taken together, these data clearly demonstrate that
TLQP-21 can suppress apoptosis induced by multiple agents,
thereby providing a likely mechanism by which this peptide
preserves b-cell mass in the context of the ZDF model of T2D.
Given that TLQP-21 treatment of rat islets causes an increase
in cAMP levels, we reasoned that its ability to suppress islet cell
death may be dependent on the cAMP-dependent kinase, PKA.
Additionally, Akt has been implicated as a component of GLP-
1R-mediated cell survival, and was therefore also considered
as a candidate mediator of the TLQP-21 protective mechanism
(Wang et al., 2004). Treatment of rat islets with the PKA inhibitor
H89, or the PI3 kinase inhibitor LY294002 blocked the ability of
TLQP-21 to protect against ER stress-related (thapsigargin-
induced) cell death (Figure 7A). In contrast, the MEK inhibitor
U0126 had no effect on TLQP-21-mediated protection. Chronic
GLP-1R signaling can indirectly activate Akt via enhanced
IGF-1R signaling (Cornu et al., 2009; Jhala et al., 2003). This is
thought to occur via PKA activation of CREB and subsequent
CREB-mediated upregulation of the IGF-1R and/ or IRS-2 (Fig-
ure 7B). Pretreatment of rat islets with the IGF-1R/ insulin
receptor inhibitor OSI 906 abrogated both TLQP-21- and
exendin-4-mediated protection against thapsigargin-induced
apoptosis (Figure 7C). However, we were unable to attribute
changes in IGF-1R signaling mediated by TLQP-21 or Ex-4 to
increases in IGF-1R or IRS-2 protein expression (Figure S3), as
previously suggested (Cornu et al., 2010; Jhala et al., 2003).
Nevertheless, we were able to demonstrate the ability of chronic
TLQP-21 and Ex-4 treatments to enhance glucose-stimulated
Akt activation (Figure S3) as previously documented for Ex-4.Cell Metabolism 16,DISCUSSION
Type 2 diabetes (T2D) occurs as a result
of several distinct metabolic lesions,
including impaired insulin action in fat
and muscle, a failure to control hepatic
glucose output, and slow developmentof insulinopenia due to loss of b-cell mass and function. Because
b-cell decompensation is often the last metabolic lesion to
appear and the one that heralds diabetes onset, interest in iden-
tifying new strategies for preserving and/or restoring functional
b-cell mass is high.
The role of the VGF-derived peptide TLQP-21 in preserving
islet b-cell mass and function described herein emerged through
our studies of the effects of the homeobox transcription factor
Nkx6.1 in adult islets (Schisler et al., 2008, 2005). In comparing
the effects of Nkx6.1 and Pdx-1 overexpression in rat islets,
we noticed that only Nkx6.1 is able to enhance GSIS (Figure 1).
VGF emerged from this analysis as the most strongly Nkx6.1-
upregulated and Pdx-1-unaffected gene (Table S1). Our subse-
quent experiments demonstrate that upregulation of VGF is
required for Nkx6.1-mediated enhancement of GSIS, and that
VGF overexpression is sufficient to drive the improved glucose
response.
VGF was originally described as a growth factor-regulated
transcript in PC12 cells (Salton, 1991; Salton et al., 1991), and
subsequently shown to be expressed inmultiple neuroendocrine
tissues in the central nervous system, including the hypothal-
amus and hippocampus (Ferri et al., 1992; van den Pol et al.,
1989) as well as in pancreatic islet cells (Cocco et al., 2007),
including b-cells. VGF is processed by the subtilisin-like prote-
ases PC1/3 and/or PC2. Similar to pro-opiomelanocortin and
proglucagon, depending upon the prevalence of these process-
ing enzymes within VGF expressing cells, distinct VGF peptides
with potentially separate biological functions may be generated.
Much of our current understanding of VGF function(s) has been
derived from the targeted deletion of VGF in mice (Hahm et al.,
1999; Watson et al., 2005). These animals display improved33–43, July 3, 2012 ª2012 Elsevier Inc. 39
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Figure 6. TLQP-21 Reduces Apoptosis
Caused by Multiple Agents
(A–C) Primary rat islets were pretreated for 24 hr
with DMSO, TLQP-21 (100nM) or Ex-4 (20nM)
followed by overnight incubation with thapsigargin
(1 mM). Non-thapsigargin treated (control) islets
were also included. Following incubation, islet
cells were dispersed onto coverslips and stained
for nicked DNA using TUNEL (red). Insulin (green)
and DAPI (blue) were used as counter stains.
Representative micrographs of islets that were
pretreated with either DMSO (A) or TLQP-21 (B)
followed by thapsigargin treatment are shown.
(C) Percentage of TUNEL positive nuclei were
determined (1700 nuclei per experiment) using
ImageJ software.
(D) Rat islets were treated with etoposide (0.2 mM)
for 72 hr. DMSO, TLQP-21 (50 nM), exendin-4
(20 nM), or forskolin (5 nM) were added to the
media (daily) for the duration of the experiment
(72 hr). Islet cells were assayed for Alexa
Fluor 488-conjugated Annexin V staining via flow
cytometry. (C and D) Data represent the mean ±
SEM from four to six independent experiments.
*p% 0.05, **p < 0.01.
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TLQP-21 Preserves Islet b-Cell Mass and Functioninsulin sensitivity, and have reduced islet cell mass, normal islet
cell architecture, and a significant decrease in circulating insulin
levels. More specific studies of VGF peptides such as TLQP-21
or AQEE-30 have mainly evaluated their effects when adminis-
tered centrally. For example, intracerebroventricular (i.c.v.) infu-
sion of TLQP-21 was shown to cause weight loss and protect
against diet-induced obesity (Bartolomucci et al., 2006), with
these effects ascribed variously to decreases in food intake
and gastric emptying (Jethwa et al., 2007) or increased energy
expenditure (Bartolomucci et al., 2006; Watson et al., 2009) by
different groups. The complex effects of VGF on peripheral
metabolism and energy balancemake it impossible to determine
from the available data if peptides derived from this prohormone
also have cell-intrinsic effects in pancreatic islets.
The current study was therefore designed to assess the direct
effects of TLQP-21 on islet biology. Here, we show that the VGF
peptide TLQP-21 is able to potentiate GSIS in isolated rat and
human pancreatic islets. Similarly, peripheral (i.p.) administration
of TLQP-21 toWistar rats increases circulating insulin in response
to a glucose challenge, thereby enhancing glucose tolerance.
TLQP-21 stimulation of insulin secretion occurs in concert with
a rise in cAMP, suggesting that the potentiating effect of TLQP-
21 is mediated via downstream targets of activated PKA, as
with other cAMP-raising agents such as GLP-1, GIP, PACAP,
and VIP. A role for PKA in the TLQP-21 signaling pathway is sup-
ported by our observation (Figure 7A) that inhibition of PKA
blocks the ability of TLQP-21 to suppress thapsigargin-induced
islet cell death. Notably, TLQP-21 does not directly engage the in-
cretin (GLP-1R, GIPR) or VIP (VIPR2) receptors. In addition, it is
unlikely that TLQP-21 engages with these receptors in vivo,
because peripheral administration of TLQP-21 is not accompa-
nied by a reduction in gastric emptying rate or elevated heart
rate in rodents, two common effects observed with GLP-1R
agonists. Although there have been reports of TLQP-21 directly
stimulating contraction of foregut muscle strips in culture, animal
studies show that the effects of TLQP-21 on gastric emptying40 Cell Metabolism 16, 33–43, July 3, 2012 ª2012 Elsevier Inc.occur only with central administration (i.c.v. infusion) and not
peripheral injection (Severini et al., 2009), consistentwith the find-
ings reported here. Taken together, our data demonstrates simi-
larities of theTLQP-21 signalingpathwaywith thoseusedbyother
b-cell secretagogues such as GLP-1, but also shows clearly that
TLQP-21operates viaaunique receptor system.Our findings also
imply that peripherally administeredTLQP-21 does not effectively
cross the blood/brain barrier to engage central signaling path-
ways. Consistent with this idea, chronic peripheral injection of
TLQP-21 did not alter body weight in our ZDF rat study, nor did
acute injection alter insulin sensitivity, suggesting that the effects
of TLQP-21 on these metabolic variable reported by others were
reliant on the central mode of administration (Bartolomucci et al.,
2009; Bartolomucci et al., 2006; Watson et al., 2005).
In addition to the acute potentiating effect of TLQP-21 onGSIS
and protection against ER stress and DNA damage-related cell
death in vitro, chronic peripheral injection of TLQP-21 was able
to preserve islet cell mass and slow the onset of hyperglycemia
in a rodent model of T2D. While full understanding of the thera-
peutic implications of our findings will require further investiga-
tion, our demonstration that TLQP-21 operates via a distinct
receptor system relative to the incretins suggest that it may ulti-
mately represent a new antidiabetogenic agent. It may seem
surprising that the antidiabetogenic effects of TLQP-21
observed in ZDF rats occurred with a regimen of every other
day injection. In this regard it should be noted that similar long-
lasting effects of GLP-1/exendin-4 have been also reported
despite its very short half-life. For example, once daily injection
of exendin-4 in diabetic db/db mice caused sustained lowering
of blood glucose, and a similar regimen improved glucose toler-
ance in Zucker rats (Greig et al., 1999; Szayna et al., 2000). Simi-
larly, a 48 hr infusion of GLP-1 into ZDF rats resulted in sustained
improvement of glucose tolerance for as long as 3 weeks after
peptide administration (Hui et al., 2002).
At the current state of technology, an apparent hurdle to
considering TLQP-21 as a therapeutic agent is the rather high
- H89 LY294002 U0126
0.0
2.0
4.0
6.0
8.0 DMSO
TLQP-21
T
U
N
E
L
 p
o
s
it
iv
e
c
e
ll
s
 (
%
)
Tg (1 M; 18 h)
*
*
Tg Tg + OSI 906
0
2
4
6
8
10
12
DMSO
TLQP-21
Ex-4
* *
T
U
N
E
L
 p
o
s
it
iv
e
c
e
ll
s
 (
%
)
Ex-4/GLP-1 
PKA 
CREB 
PI3K/Akt
Islet cell 
protection 
IGF2/IGF1R 
TLQP-21 
H89 
OSI 906 
LY294002 
m
A B
C
Figure 7. Inhibition of PKA and Akt Impair
TLQP-21-Mediated Protection against Islet
Cell Death
(A and C) Primary rat islets were pretreated for 6 hr
with DMSO or TLQP-21 (100nM) in the presence of
H89 (10 nM), LY294002 (10nM), orU0126 (5 nM) (A)
or OSI 906 (100nM) (C) as indicated followed by
overnight (18 hr) incubation with thapsigargin
(1 mM). (A and C) Following incubation, islet cells
were dispersed onto coverslips and stained for
nicked DNA using TUNEL. Percentage of TUNEL
positive nuclei were determined (2000 nuclei per
experiment) using ImageJ software. Data repre-
sent the mean ± SEM from four to seven indepen-
dent experiments. *p% 0.05.
(B) Proposed model of the GLP-1/Ex-4 and TLQP-
21 antiapoptotic signaling pathway.
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TLQP-21 Preserves Islet b-Cell Mass and Functiondose required (2 mmol/kg) to observe effects on insulin secre-
tion in vivo as compared to GLP-1/ Ex-4 (1–10 nmol/kg). This
is in contrast to the similar concentrations of TLQP-21 and
GLP-1 required to potentiate GSIS and promote islet cell survival
in vitro (50 nM TLQP-21 versus 20 nM Ex-4). A possible explana-
tion for this discrepancy is a rapid turnover of TLQP-21 in
plasma, such that a large bolus is required to reach the target
tissue (i.e., pancreatic islets). Elucidation of the degradation
pathway of TLQP-21, with particular focus on inactivating
proteolytic cleavage events, will be required in order to under-
stand the pharmacokinetics of this peptide. Identification of the
DPP-4-catalyzed cleavage event proved to be amajor milestone
in the development of methods for detecting active forms of
GLP-1, and for development of new analogs that are resistant
to enzymatic cleavage (Deacon et al., 1995; Kieffer et al.,
1995). We suspect that it will ultimately be possible to design
more stable TLQP-21 analogs, and that these agents will be
useful for defining the full therapeutic potential of this molecule.
Alternatively, it may be possible to take advantage of the expres-
sion and secretion of VGF/TLQP-21 from the islets themselves.
In this regard, we show here that glucose is able to stimulate
secretion of TLQP-21 from human islets. This finding suggests
that it may be possible to define strategies for enhancing produc-
tion of TLQP-21 fromendogenous islets as ameans of protecting
islet mass and enhancing islet function in the prediabetic state.
Further studies focused on defining the role of locally produced
TLQP-21 on islet biology will be important for development of
such strategies.
EXPERIMENTAL PROCEDURES
Note that some of the reagents and common procedures used in this study are
described in Supplemental Experimental Procedures.
Glucose-Stimulated Insulin Secretion
Islets were isolated from male Wistar rats at 12–16 weeks of age as described
(Schisler et al., 2008). Insulin secretion was measured by static incubation of 3
groups of 20 islets per condition as described previously (Schisler et al., 2008,
2005), in secretion assay buffer (SAB) containing 2.5mM Glc for 1 hr at 37CCell Metabolism 16,(basal) followed by incubation in SAB containing
16.7 mM Glc for 1 hr (stimulatory). Hormones
(exendin-4, TLQP-21/30/42, AQEE-30) were in-
cluded as indicated. Insulin was measured inSAB using the Coat-a-Count kit (Siemens). Islets were lysed in RIPA buffer
and total protein determined by BCA (Pierce), and insulin content determined
as described (Schisler et al., 2008, 2005).
TLQP-21 Secretion and Content
Media was collected from human islets following static incubations of 5–6
groups of 50 islets in SAB containing 2.5 mM Glc for 2 hr at 37C (basal),
followed by incubation in SAB containing 16.7 mM Glc for 2 hr (stimulatory).
Islets were lysed in RIPA buffer and total protein determined by BCA (Pierce).
Secreted TLQP-21 was assayed from the media, and total TLQP-21 content
was determined from diluted islet cell lysates, using a human TLQP-21-
specific ELISA (Bachem). Human islets were obtained from the Integrated Islet
Distribution Program (IIDP).
cAMP Determination and Receptor Transfection Studies
For cAMP measurements, primary rat islets were prepared as for insulin
secretion assays, except the incubation at stimulatory glucose was for
30min in the presence of 0.1mM isobuytlmethylxanthine (IBMX). HEK293 cells
were transiently transfected with plasmids containing GLP-1R, GIPR, VIPR2,
or mock (no plasmid), and were preincubated in SAB for 1.5 hr followed by
a 15 min incubation in fresh SAB containing DMSO, exendin-4 (20 nM), GIP
(10 nM), VIP (10 nM) or TLQP-21 (50 nM) in the presence of IBMX. Islet and
HEK293 cell extracts were assayed using the cAMP EIA kit from Biomedical
Technologies, Inc.
Gastric Emptying Studies
For the acetaminophen absorption test, overnight (12 hr) fasted male Wistar
rats received a 100mg/kg oral gavage of acetaminophen (children’s pain killer)
20 min postinjection (i.p.) of saline or peptide (4.5 mg/kg TLQP-21, 4.5 mg/kg
of a scrambled peptide of identical amino acid composition as TLQP-21
[SCR-21], or 10 ug/kg exendin-4). Blood was sampled from either the tail or
saphenous veins at the indicated times. Serum was assayed for acetamino-
phen and insulin using a colormetric assay (Genzyme) and ELISA (Millipore),
respectively. For the solid-phase gastric clearance test, fasted animals were
refed for 1 hr and then injected i.p. with saline or one of the 3 peptides
described above. At 3 hr postinjection, animals were sacrificed, stomach
contents retrieved and dried in an oven. The percentage food content remain-
ing in the stomach was determined from the dry weight of stomach contents
divided by the total amount of food consumed per animal multiplied by 100.
Heart Rate Measurements
Male Wistar rats were sedated using 250 mg/kg tribromoethanol (Avertin).
Continuous ECG recording were obtained with subcutaneously placed 29-
gauge needle electrodes in both forelimbs in a Lead I configuration using the33–43, July 3, 2012 ª2012 Elsevier Inc. 41
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TLQP-21 Preserves Islet b-Cell Mass and FunctionML138 Octal Bioamp (ADInstruments Colorado Springs, CO) connected to
a Powerlab 16/30 acquisition system (ADInstruments). After establishment of
baseline heart rate recordings (5–10 min), animals received i.p. injections of
either saline or peptide (4.5 mg/kg TLQP-21, 4.5 mg/kg SCR-21, or 10 mg/kg
exendin-4). ECG data was analyzed for heart rate using LabChart Pro 7.2
Software (AD Instruments).
Chronic Peptide Treatment Study
Seven-week-old male Zucker Diabetic Fatty (fa/fa) rats were randomly
assigned to 1 of 3 groups receiving TLQP-21, SCR-21, or saline. 5 mg/kg
peptide or an equivalent volume of saline were injected at a frequency of every
other day for 4 wks. Glucose was measured in blood collected weekly from ad
lib fed rats via the saphenous vein in the morning. Insulin and glucagon levels
were determined using a rat/mouse insulin ELISA (Millipore) and rat glucagon
RIA (Millipore), respectively.
In Vitro Apoptosis Assay
Pools of 50 islets were treated with TLQP-21 (100 nM), exendin-4 (20 nM),
H89 (10 nM), LY294002 (10 nM), U0126 (5 nM), OSI 906 (100 nM) or vehicle
(DMSO) for 6–24 hr followed by overnight (18 hr) incubation with thapsigargin
(1 mM). Islets were dispersed with trypsin/EDTA and attached to poly-D-lysine
coated coverslips (BD). For detection of apoptosis, islet cells were stained
using the In situ Cell Death detection kit (Roche). Insulin and DAPI were
used as counter stains. Five to seven images containing200 nuclei per image
per slide were evaluated for TUNEL staining using ImageJ software.
Percentage of TUNEL positive cells was determined as the ratio of TUNEL
stained cells to total nuclei x 100. In a separate series of studies, pools of 50
islets were treated with DMSO or etoposide (0.2 mM) for 72 hr in the presence
of TLQP-21 (50 nM), exendin-4 (20 nM), or forskolin (5 nM). Islets were
dispersed using trysin/EDTA and stained with Alexa Fluor 488-conjugated
Annexin V (Invitrogen) and propidium iodide (Sigma). Data were collected
using a FACScan analyzer and analyzed using WinMDI 2.9 software.
Statistical Analysis
Data are presented as the mean ± SEM. For statistical significance
determinations, data were analyzed by the two-tailed paired, Student’s t test
or by ANOVA with Bonferonni post hoc analysis for multiple group
comparisons.
Abbreviations
Area under the curve (AUC); glucagon-like peptide-1 (GLP-1); glucose-depen-
dent insulinotropic polypeptide (GIP); glucose-stimulated insulin secretion
(GSIS); Heart rate (HR); intracerebroventricular (i.c.v.); intraperitoneal (i.p.);
intraperitoneal glucose tolerance test (IPGTT); secretion assay buffer (SAB);
terminal deoxynucleotide transferase-mediated 20-deoxyuridine 50-triphos-
phate nick-end labeling (TUNEL); Type 2 diabetes (T2D); vasoactive intestinal
peptide (VIP); a scrambled peptide of identical amino acid composition as
TLQP-21 (SCR-21); Zucker Diabetic Fatty (ZDF) rats.
SUPPLEMENTAL INFORMATION
Supplemental Information includes Supplemental Experimental Pro-
cedures, Supplemental References, three figures, and one table and can
be found with this article online at http://dx.doi.org/10.1016/j.cmet.2012.
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